3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
2
Conditions
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Recurrence
2
Meningioma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
Muscle Invasive Bladder Cancer
1
Lung Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
DLBCL
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Advanced Solid Malignancies
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
8
Bevacizumab
8
toripalimab
7
senaparib
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Gemcitabine
5
Fluorouracil
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Carboplatin
4
spartalizumab
3
sintilimab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumor
×
vistusertib
×
Clear all
NCT03166176
2019-05-20
TSC1/2_SC
Samsung Medical Center
Phase 2
Withdrawn
NCT03166904
2019-05-20
RICTOR_SC
Samsung Medical Center
Phase 2
Withdrawn